These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1094 related articles for article (PubMed ID: 1676590)
21. [Drug therapy of chronic inflammatory bowel disease--reliable standards and new developments]. Fischbach W Leber Magen Darm; 1992 Mar; 22(2):49-55. PubMed ID: 1350043 [TBL] [Abstract][Full Text] [Related]
22. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine. Nakajima H; Munakata A; Yoshida Y J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870 [TBL] [Abstract][Full Text] [Related]
23. Current medical therapy for inflammatory bowel disease. Bonner GF South Med J; 1996 Jun; 89(6):556-66. PubMed ID: 8638193 [TBL] [Abstract][Full Text] [Related]
24. [Local or systemic treatment of inflammatory bowel diseases?]. Schmassmann A; Halter F Ther Umsch; 1993 Feb; 50(2):94-9. PubMed ID: 8096092 [TBL] [Abstract][Full Text] [Related]
25. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease. Clemett D; Markham A Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042 [TBL] [Abstract][Full Text] [Related]
26. [Therapeutic efficacy of 5-ASA molecules in idiopathic intestinal inflammatory diseases: critical review]. Van Gossum A Acta Gastroenterol Belg; 1992; 55(5-6):462-71. PubMed ID: 1363167 [TBL] [Abstract][Full Text] [Related]
27. Comparative tolerability of therapies for ulcerative colitis. Ardizzone S; Bianchi Porro G Drug Saf; 2002; 25(8):561-82. PubMed ID: 12113642 [TBL] [Abstract][Full Text] [Related]
28. Drug insight: aminosalicylates for the treatment of IBD. Nielsen OH; Munck LK Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853 [TBL] [Abstract][Full Text] [Related]
36. [Drug therapy of chronic inflammatory intestinal diseases--current status of 5-aminosalicylic acid]. Schölmerich J; Gerok W Wien Klin Wochenschr; 1986 Nov; 98(22):762-9. PubMed ID: 2880425 [TBL] [Abstract][Full Text] [Related]
37. Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Wadworth AN; Fitton A Drugs; 1991 Apr; 41(4):647-64. PubMed ID: 1711964 [TBL] [Abstract][Full Text] [Related]
38. Maintenance of remission in Crohn's disease: current and emerging therapeutic options. Brookes MJ; Green JR Drugs; 2004; 64(10):1069-89. PubMed ID: 15139787 [TBL] [Abstract][Full Text] [Related]
39. Medical management of Crohn's disease. Cottone M; Renna S; Orlando A; Mocciaro F Expert Opin Pharmacother; 2011 Nov; 12(16):2505-25. PubMed ID: 21988215 [TBL] [Abstract][Full Text] [Related]
40. Medical therapy of inflammatory bowel disease for the 21st century. Robinson M Eur J Surg Suppl; 1998; (582):90-8. PubMed ID: 10029372 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]